PharmaCan Capital Corp Stock Toronto S.E.
Equities
MJN
CA7171151094
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- CAD | - |
Sales 2024 * | 141M 104M | Sales 2025 * | 170M 125M | Capitalization | 1.35B 992M |
---|---|---|---|---|---|
Net income 2024 * | -17M -12.47M | Net income 2025 * | 7M 5.13M | EV / Sales 2024 * | 1.04 x |
Net cash position 2024 * | 1.21B 884M | Net cash position 2025 * | 1.22B 892M | EV / Sales 2025 * | 0.8 x |
P/E ratio 2024 * |
-92.6
x | P/E ratio 2025 * |
-304
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.37% |
Latest transcript on PharmaCan Capital Corp
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 37 | 15-11-05 | |
James Holm
DFI | Director of Finance/CFO | 41 | 22-11-13 |
Arye Weigensberg
CTO | Chief Tech/Sci/R&D Officer | 41 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 48 | 21-06-24 | |
James Rudyk
BRD | Director/Board Member | 57 | 18-01-31 |
Jason Adler
BRD | Director/Board Member | 52 | 16-07-11 |
1st Jan change | Capi. | |
---|---|---|
+37.29% | 6.02B | |
-21.28% | 4.19B | |
+4.52% | 3.25B | |
-18.16% | 2.87B | |
-7.70% | 2.37B | |
+41.50% | 1.89B | |
-4.05% | 1.58B | |
-15.56% | 1.54B | |
-14.62% | 1.5B |
- Stock Market
- Equities
- CRON Stock
- MJN Stock